Symbols / SQZB $0.02 +0.00% SQZ Biotechnologies Company

Healthcare • Biotechnology • United States • PNK
SQZB Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO —
Exch · Country PNK · United States
Market Cap 707.79K
Enterprise Value 11.99M
Income -71.64M
Sales 12.12M
FCF (ttm) -29.51M
Book/sh 0.06
Cash/sh 0.35
Employees 53
Insider 10d —
IPO Oct 30, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.00
PEG —
P/S 0.06
P/B 0.38
P/C —
EV/EBITDA -0.20
EV/Sales 0.99
Quick Ratio 1.15
Current Ratio 1.37
Debt/Eq 1,141.52
LT Debt/Eq —
EPS (ttm) -2.43
EPS next Y -22.75
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2023-11-08
Earnings (prior) 2023-11-08
ROA -41.14%
ROE -203.37%
ROIC —
Gross Margin 0.00%
Oper. Margin -5.01%
Profit Margin 0.00%
Shs Outstand 29.49M
Shs Float 26.14M
Insider Own 0.00%
Instit Own 0.01%
Short Float 3.03%
Short Ratio 27.26
Short Interest 811.15K
52W High 0.05
vs 52W High -52.00%
52W Low 0.02
vs 52W Low 4.35%
Beta 0.33
Impl. Vol. —
Rel Volume 18.42
Avg Volume 1.36K
Volume 25.00K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.02
Price $0.02
Change 0.00%
About

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV and SQZ-eAPC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.02
Latest analyst target
3. DCF / Fair value
$-18.01
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.02
Low
—
High
—
Mean
—
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2022-12-31 2021-12-31
Total Revenue
21.03
-22.40%
27.10
Operating Revenue
21.03
-22.40%
27.10
Operating Expense
96.85
+1.03%
95.87
Research And Development
70.98
+1.19%
70.15
Selling General And Administration
26.32
+2.33%
25.72
General And Administrative Expense
26.32
+2.33%
25.72
Salaries And Wages
12.88
+1.58%
12.69
Other Gand A
13.43
+3.07%
13.03
Other Operating Expenses
-0.45
—
Total Expenses
96.85
+1.03%
95.87
Operating Income
-75.83
-10.26%
-68.77
Total Operating Income As Reported
-80.68
-17.33%
-68.77
EBITDA
-64.14
-11.09%
-57.74
Normalized EBITDA
-59.28
-2.67%
-57.74
Reconciled Depreciation
11.68
+5.93%
11.03
EBIT
-75.83
-10.26%
-68.77
Total Unusual Items
-4.86
0.00
Total Unusual Items Excluding Goodwill
-4.86
0.00
Special Income Charges
-4.86
0.00
Restructuring And Mergern Acquisition
4.86
0.00
Net Income
-79.46
-15.60%
-68.74
Pretax Income
-79.46
-15.60%
-68.74
Net Non Operating Interest Income Expense
1.22
+3297.22%
0.04
Net Interest Income
1.22
+3297.22%
0.04
Interest Income Non Operating
1.22
+3297.22%
0.04
Interest Income
1.22
+3297.22%
0.04
Other Income Expense
-4.86
-60675.00%
-0.01
Other Non Operating Income Expenses
-0.00
+62.50%
-0.01
Tax Rate For Calcs
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
Net Income Including Noncontrolling Interests
-79.46
-15.60%
-68.74
Net Income From Continuing Operation Net Minority Interest
-79.46
-15.60%
-68.74
Net Income From Continuing And Discontinued Operation
-79.46
-15.60%
-68.74
Net Income Continuous Operations
-79.46
-15.60%
-68.74
Normalized Income
-74.61
-8.53%
-68.74
Net Income Common Stockholders
-79.46
-15.60%
-68.74
Diluted EPS
-2.76
-10.84%
-2.49
Basic EPS
-2.76
-10.84%
-2.49
Basic Average Shares
28.81
+4.47%
27.58
Diluted Average Shares
28.81
+4.47%
27.58
Diluted NI Availto Com Stockholders
-79.46
-15.60%
-68.74
Line Item Trend 2022-12-31 2021-12-31
Total Assets
99.90
-55.83%
226.15
Current Assets
68.20
-54.72%
150.63
Cash Cash Equivalents And Short Term Investments
63.71
-55.61%
143.51
Cash And Cash Equivalents
63.71
-55.61%
143.51
Receivables
0.38
-87.59%
3.10
Accounts Receivable
0.00
-100.00%
3.00
Other Receivables
0.38
+304.21%
0.10
Prepaid Assets
4.11
+2.09%
4.03
Total Non Current Assets
31.70
-58.03%
75.52
Net PPE
29.39
-59.68%
72.89
Gross PPE
35.17
-54.56%
77.40
Accumulated Depreciation
-5.78
-28.11%
-4.51
Properties
0.00
0.00
Machinery Furniture Equipment
7.16
+2.59%
6.98
Other Properties
27.43
-60.72%
69.84
Leases
0.58
+0.00%
0.58
Non Current Deferred Assets
—
0.32
Other Non Current Assets
2.31
-12.29%
2.63
Total Liabilities Net Minority Interest
42.75
-58.16%
102.18
Current Liabilities
21.84
-34.26%
33.22
Payables And Accrued Expenses
11.99
+54.86%
7.74
Payables
2.51
-36.77%
3.97
Accounts Payable
2.51
-36.77%
3.97
Current Accrued Expenses
9.48
+151.38%
3.77
Pensionand Other Post Retirement Benefit Plans Current
2.58
-15.20%
3.04
Current Debt And Capital Lease Obligation
6.56
-33.96%
9.94
Current Capital Lease Obligation
6.56
-33.96%
9.94
Current Deferred Liabilities
0.71
-94.28%
12.51
Current Deferred Revenue
0.71
-94.28%
12.51
Total Non Current Liabilities Net Minority Interest
20.91
-69.68%
68.95
Long Term Debt And Capital Lease Obligation
20.91
-65.01%
59.76
Long Term Capital Lease Obligation
20.91
-65.01%
59.76
Non Current Deferred Liabilities
0.00
-100.00%
9.20
Non Current Deferred Revenue
0.00
-100.00%
9.20
Stockholders Equity
57.15
-53.90%
123.98
Common Stock Equity
57.15
-53.90%
123.98
Capital Stock
0.03
+3.57%
0.03
Common Stock
0.03
+3.57%
0.03
Preferred Stock
0.00
0.00
Share Issued
29.49
+4.83%
28.13
Ordinary Shares Number
29.49
+4.83%
28.13
Additional Paid In Capital
332.09
+3.96%
319.46
Retained Earnings
-274.97
-40.64%
-195.51
Total Equity Gross Minority Interest
57.15
-53.90%
123.98
Total Capitalization
57.15
-53.90%
123.98
Working Capital
46.36
-60.51%
117.41
Invested Capital
57.15
-53.90%
123.98
Total Debt
27.47
-60.58%
69.69
Capital Lease Obligations
27.47
-60.58%
69.69
Net Tangible Assets
57.15
-53.90%
123.98
Tangible Book Value
57.15
-53.90%
123.98
Line Item Trend 2022-12-31 2021-12-31
Operating Cash Flow
-83.55
-1.72%
-82.14
Cash Flow From Continuing Operating Activities
-83.55
-1.72%
-82.14
Net Income From Continuing Operations
-79.46
-15.60%
-68.74
Depreciation Amortization Depletion
11.68
+5.93%
11.03
Depreciation
11.68
+5.93%
11.03
Depreciation And Amortization
11.68
+5.93%
11.03
Stock Based Compensation
8.40
-1.20%
8.51
Operating Gains Losses
0.03
+371.43%
0.01
Gain Loss On Sale Of PPE
0.03
+371.43%
0.01
Change In Working Capital
-24.20
+26.51%
-32.94
Change In Receivables
3.00
+370.76%
-1.11
Changes In Account Receivables
3.00
+370.76%
-1.11
Change In Prepaid Assets
-0.37
-181.09%
0.46
Change In Payables And Accrued Expense
3.82
+383.31%
0.79
Change In Accrued Expense
5.25
+1953.36%
-0.28
Change In Payable
-1.42
-232.40%
1.07
Change In Account Payable
-1.42
-232.40%
1.07
Change In Other Working Capital
-20.99
+12.08%
-23.87
Change In Other Current Assets
0.32
+200.00%
-0.32
Change In Other Current Liabilities
-9.99
-12.44%
-8.88
Investing Cash Flow
-0.49
+20.39%
-0.61
Cash Flow From Continuing Investing Activities
-0.49
+20.39%
-0.61
Net PPE Purchase And Sale
-0.49
+20.39%
-0.61
Purchase Of PPE
-0.52
+14.85%
-0.61
Sale Of PPE
0.03
0.00
Capital Expenditure
-0.52
+14.85%
-0.61
Net Investment Purchase And Sale
—
0.00
Sale Of Investment
—
0.00
Financing Cash Flow
4.23
-92.43%
55.91
Cash Flow From Continuing Financing Activities
4.23
-92.43%
55.91
Net Common Stock Issuance
4.07
-92.79%
56.40
Proceeds From Stock Option Exercised
0.17
-88.23%
1.41
Net Other Financing Charges
—
-1.90
Changes In Cash
-79.80
-197.29%
-26.84
Beginning Cash Position
145.82
-15.55%
172.66
End Cash Position
66.01
-54.73%
145.82
Free Cash Flow
-84.07
-1.60%
-82.75
Amortization Of Securities
—
0.00
Common Stock Issuance
4.07
-92.79%
56.40
Issuance Of Capital Stock
4.07
-92.79%
56.40
Net Preferred Stock Issuance
—
0.00
Preferred Stock Issuance
—
0.00
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category